(0.32%) 5 116.32 points
(0.31%) 38 357 points
(0.37%) 15 988 points
(-0.97%) $83.04
(5.36%) $2.03
(0.33%) $2 355.00
(0.54%) $27.69
(4.26%) $961.35
(-0.27%) $0.932
(-0.45%) $10.98
(-0.59%) $0.796
(1.63%) $93.37
@ $6.26
発行日: 15 2月 2024 @ 01:00
リターン: -73.81%
前回のシグナル: 2月 14 - 23:30
前回のシグナル:
リターン: -1.57 %
Live Chart Being Loaded With Signals
Pacific Biosciences of California, Inc. designs, develops, and manufactures sequencing systems to resolve genetically complex problems. The company provides PacBio's Systems, which conduct, monitor, and analyse biochemical sequencing reactions; consumable products, including single molecule real-time (SMRT) cells; and various reagent kits designed for specific workflow, such as template preparation kit to convert DNA into SMRTbell double-stranded DNA library formats, including molecular biology reagents, such as ligase, buffers, and exonucleases...
Stats | |
---|---|
本日の出来高 | 6.07M |
平均出来高 | 9.80M |
時価総額 | 439.36M |
EPS | $0 ( 2024-02-15 ) |
次の収益日 | ( $-0.260 ) 2024-05-07 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -1.360 |
ATR14 | $0.00800 (0.49%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-03-15 | Ordonez Kathy | Buy | 37 106 | Common Stock |
2024-03-15 | Ordonez Kathy | Buy | 324 515 | Common Stock |
2024-03-15 | Ordonez Kathy | Sell | 324 515 | Stock Option (right to buy) |
2024-03-15 | Ordonez Kathy | Sell | 37 106 | Stock Option (right to buy) |
2024-03-06 | Meline David W | Buy | 40 000 | Common Stock |
INSIDER POWER |
---|
70.23 |
Last 98 transactions |
Buy: 9 423 437 | Sell: 6 701 044 |
ボリューム 相関
Pacific Biosciences of 相関
10 最も正の相関 |
---|
10 最も負の相関 |
---|
知っていましたか?
相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関(1つの変数が増加すると、もう一方は減少する)、1は完全な正の相関(1つの変数が増加すると、もう一方も増加する)、0は相関がないことを示します(変数間に関係がない)。
相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。
Pacific Biosciences of 相関 - 通貨/商品
Pacific Biosciences of 財務諸表
Annual | 2023 |
収益: | $200.52M |
総利益: | $40.35M (20.12 %) |
EPS: | $-1.210 |
FY | 2023 |
収益: | $200.52M |
総利益: | $40.35M (20.12 %) |
EPS: | $-1.210 |
FY | 2022 |
収益: | $128.30M |
総利益: | $49.04M (38.22 %) |
EPS: | $-1.320 |
FY | 2021 |
収益: | $130.51M |
総利益: | $58.86M (45.10 %) |
EPS: | $-0.890 |
Financial Reports:
No articles found.
Pacific Biosciences of
Pacific Biosciences of California, Inc. designs, develops, and manufactures sequencing systems to resolve genetically complex problems. The company provides PacBio's Systems, which conduct, monitor, and analyse biochemical sequencing reactions; consumable products, including single molecule real-time (SMRT) cells; and various reagent kits designed for specific workflow, such as template preparation kit to convert DNA into SMRTbell double-stranded DNA library formats, including molecular biology reagents, such as ligase, buffers, and exonucleases. It also offers binding kits, such as modified DNA polymerase used to bind SMRTbell libraries to the polymerase in preparation for sequencing; and sequencing kits comprise reagents required for on-instrument, real-time sequencing, including the phospholinked nucleotides. The company serves research institutions; commercial laboratories; genome centers; public health labs, hospitals and clinical research institutes, contract research organizations, and academic institutions; pharmaceutical companies; and agricultural companies. It markets its products through a direct sales force in North America and Europe, as well as through distribution partners in Asia, Europe, the Middle East, Africa, and Latin America. Pacific Biosciences of California, Inc. has a development and commercialization agreement with Invitae Corporation. The company was formerly known as Nanofluidics, Inc. and changed its name to Pacific Biosciences of California, Inc. in 2005. Pacific Biosciences of California, Inc. was incorporated in 2000 and is headquartered in Menlo Park, California.
について ライブシグナル
このページで提示されるライブシグナルは、NA を買う時や売る時を判断するのに役立ちます。シグナルには1分以上の遅延があります。市場シグナルには誤りやミスの可能性があるため、ライブ取引シグナルは決定的ではなく、getagraph.comはこれらのシグナルに基づく任意の行動について責任を負いません。詳細については、利用規約で説明されているように、技術分析指標に基づいています。